Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study
Patch, Christine, Charlton, Judith, Roderick, Paul J. and Gulliford, Martin C. (2011) Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. American Journal of Kidney Diseases, 57, (6), 856-862. (doi:10.1053/j.ajkd.2011.01.023). (PMID:21458899).
Full text not available from this repository.
Background: This study aimed to estimate the association between antihypertensive therapy and mortality in patients with autosomal dominant polycystic kidney disease (ADPKD).
Study Design: Cohort study.
Setting & Participants: Participants with ADPKD from the UK General Practice Research Database older than 15 years between 1991 and 2008.
Predictors: Use of 5 major classes of antihypertensive drug.
Outcomes: Deaths, new renal replacement therapy events.
Measurements: Random-effects Poisson models were adjusted for age, sex, year of entry into the cohort, calendar year, prevalent coronary heart disease, stroke, diabetes, hyperlipidemia, and lipid-lowering therapy.
Results: From 1991-2008, there were 2,085 cases of ADPKD, with 1,877 contributing person-time for ages older than 15 years. In 1991, antihypertensive drugs were not prescribed for 68% of participants, which decreased to 38% by 2008. The proportion for which 1 class of antihypertensive drug was prescribed increased from 19% in 1991 to 24% in 2008; 2 classes, from 11% to 22%; 3 classes, from 2% to 11%; and 4 or 5 classes, from 1% to 5%. In 1991, drugs acting on the renin-angiotensin system were prescribed for only 7% of participants; by 2008, this had increased to 46%. There was evidence of a trend toward decreasing mortality as the number of antihypertensive drug classes prescribed in a year increased. For participants with 3 classes of drugs prescribed, the incident rate ratio was 0.11 (95% CI, 0.05-0.21; P < 0.001). Each annual increment in year of entry into the cohort was associated with a 6% (95% CI, 2%-10%; P = 0.008) decrease in mortality.
Limitations: Reported associations might be accounted for by unmeasured or incompletely measured confounders. These might include changes in other aspects of medical care for patients with ADPKD.
Conclusion: Increasing coverage and intensity of antihypertensive therapy is associated with decreasing mortality in people with ADPKD.
|Keywords:||polycystic kidney, autosomal dominant, hypertension, antihypertensive drugs, mortality, survival|
|Subjects:||Q Science > QR Microbiology > QR180 Immunology
Q Science > QR Microbiology > QR355 Virology
R Medicine > RB Pathology
|Divisions:||University Structure - Pre August 2011 > School of Medicine > Community Clinical Sciences
Faculty of Medicine > Primary Care and Population Sciences
|Date Deposited:||16 Jun 2011 10:54|
|Last Modified:||01 Jan 2012 08:06|
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)